Company attributes
Other attributes
Editas Medicine is a biotechnology and synthetic biology company using genetic engineering to create therapeutics for treating disease. It is headquartered in Cambridge, Massachusetts, and was founded in 2013 by Feng Zhang, J. Keith Joung, and Jennifer A. Doudna.
Editas Medicine has developed a proprietary genome editing platform based on CRISPR using different engineered variants of CRISPR effector nucleases Cas9 and Cpf1 (also known as Cas12a). The company is working on gene editing efficiency and delivery of treatment to the sight of disease. Editas Medicine is in the discovery stage of developing CRISPR gene edit treatments for the following conditions:
Leber Congenital Amaurosis 10
Usher Syndrome 2a
HSV-1
T Cells for cancer treatments
Beta Thalassemia
Sickle Cell
Cystic Fibrosis
Alpha-I Antitrypsin Deficiency
Editas Medicine was previously founded under the name Gengine by Feng Zhang, George Church, Keith Joung, David Liu all from The Broad Institute at MIT and Harvard along with Jennifer Doudna from the University of California, Berkeley. Jennifer Doudna left and co-founded Intellia Therapeutics.
